Pediatric Acute Myeloid Leukemia Treatment Outcomes: A Retrospective Cohort Study on Prognostic Factors and Survival in a Low- to Middle-Income Country

Background: Pediatric acute myeloid leukemia (AML) outcomes remain substantially lower in low- and middle-income countries (LMICs), where treatment-related mortality (TRM), treatment abandonment, and limited access to risk-adapted therapy and hematopoietic stem cell transplantation (HSCT) remain important challenges. We evaluated contemporary outcomes and factors influencing survival in children with AML treated at a tertiary center in Pakistan. Methods: We retrospectively analyzed patients aged <18 years diagnosed with AML between 2011 and 2023. Patients in main AML cohort were compared between an early era (2011–2016) and a later era (2017–2023), following institutional availability of HSCT. Overall survival (OS), event-free survival (EFS), and relapse-free survival (RFS) were estimated using Kaplan–Meier methods. Cumulative incidences of relapse and TRM were estimated using competing-risk analysis. Acute myeloid leukemia associated with Down syndrome (AML-DS) and Acute promyelocytic leukemia (APL) were analyzed separately. Results: Among 143 patients in the main AML cohort, 114 (80%) initiated therapy and 69 (60%) achieved complete remission. Induction mortality was 16%, while TRM occurred in 27% of treated patients, predominantly due to sepsis. Three-year OS, EFS, and RFS were 35%, 17%, and 38%, respectively. Survival did not differ significantly between the early and later eras (3-year OS, 37% vs. 32%, p=0.70; EFS, 20% vs. 15%, p=0.35). The 3-year cumulative incidences of relapse and TRM were 51% and 26%, respectively, with no significant differences between eras. Thirty patients relapsed; 12 received salvage therapy, of whom nine achieved a second remission. Treatment abandonment occurred throughout the treatment course, including in 16% before therapy initiation. Intermediate- and high-risk disease and higher presenting white blood cell count were associated with increased mortality on multivariable analysis. Twelve patients underwent HSCT, all in the later era. Three-year OS was 78% in AML-DS and 75% in APL. Conclusion: Pediatric AML outcomes remained limited by the combined effects of TRM, relapse, and treatment abandonment. Institutional availability of HSCT in the later era was not associated with improved population-level survival, although the small number of transplanted patients precludes conclusions regarding HSCT effectiveness. Strengthening supportive care, molecular risk stratification, treatment continuity, and timely access to salvage therapy and HSCT may improve outcomes in resource-limited settings.

Authors

Publication Details

Journal
Acta Haematologica
Published
2026-11-21
DOI
https://doi.org/10.1159/aha/abkag025
Primary Topic
Acute Myeloid Leukemia Research
Type
article
Field-Weighted Citation Impact
0.00
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
NOV
article

Pediatric Acute Myeloid Leukemia Treatment Outcomes: A Retrospective Cohort Study on Prognostic Factors and Survival in a Low- to Middle-Income Country

Syed Ibrahim Bukhari, Farrah Bashir, Naureen Mushtaq, Zehra Fadoo et al.
Acta Haematologica
Acute Myeloid Leukemia Research
article

Pediatric Acute Myeloid Leukemia Treatment Outcomes: A Retrospective Cohort Study on Prognostic Factors and Survival in a Low- to Middle-Income Country

Syed Ibrahim Bukhari, Farrah Bashir, Naureen Mushtaq, Zehra Fadoo, Asim Belgaumi, Sadaf Altaf, Abdul Hadi Shahid
article en

Abstract

Background: Pediatric acute myeloid leukemia (AML) outcomes remain substantially lower in low- and middle-income countries (LMICs), where treatment-related mortality (TRM), treatment abandonment, and limited access to risk-adapted therapy and hematopoietic stem cell transplantation (HSCT) remain important challenges. We evaluated contemporary outcomes and factors influencing survival in children with AML treated at a tertiary center in Pakistan. Methods: We retrospectively analyzed patients aged <18 years diagnosed with AML between 2011 and 2023. Patients in main AML cohort were compared between an early era (2011–2016) and a later era (2017–2023), following institutional availability of HSCT. Overall survival (OS), event-free survival (EFS), and relapse-free survival (RFS) were estimated using Kaplan–Meier methods. Cumulative incidences of relapse and TRM were estimated using competing-risk analysis. Acute myeloid leukemia associated with Down syndrome (AML-DS) and Acute promyelocytic leukemia (APL) were analyzed separately. Results: Among 143 patients in the main AML cohort, 114 (80%) initiated therapy and 69 (60%) achieved complete remission. Induction mortality was 16%, while TRM occurred in 27% of treated patients, predominantly due to sepsis. Three-year OS, EFS, and RFS were 35%, 17%, and 38%, respectively. Survival did not differ significantly between the early and later eras (3-year OS, 37% vs. 32%, p=0.70; EFS, 20% vs. 15%, p=0.35). The 3-year cumulative incidences of relapse and TRM were 51% and 26%, respectively, with no significant differences between eras. Thirty patients relapsed; 12 received salvage therapy, of whom nine achieved a second remission. Treatment abandonment occurred throughout the treatment course, including in 16% before therapy initiation. Intermediate- and high-risk disease and higher presenting white blood cell count were associated with increased mortality on multivariable analysis. Twelve patients underwent HSCT, all in the later era. Three-year OS was 78% in AML-DS and 75% in APL. Conclusion: Pediatric AML outcomes remained limited by the combined effects of TRM, relapse, and treatment abandonment. Institutional availability of HSCT in the later era was not associated with improved population-level survival, although the small number of transplanted patients precludes conclusions regarding HSCT effectiveness. Strengthening supportive care, molecular risk stratification, treatment continuity, and timely access to salvage therapy and HSCT may improve outcomes in resource-limited settings.

Acta Haematologica
Acute Myeloid Leukemia Research
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.

Laika access coming soon